A Phase I Trial of the Immunostimulant JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2017
At a glance
- Drugs JVRS 100 (Primary)
- Indications Leukaemia
- Focus Adverse reactions
- 26 Jan 2017 Planned End Date changed from 1 Oct 2015 to 19 Oct 2017.
- 04 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Jan 2014 Planned End Date changed from 1 Oct 2013 to 1 Oct 2015 as reported by ClinicalTrials.gov.